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Highlights: 
• Computational modeling and virtual screening identified hits against S100P, a 
protein target of interest in tumor progression and metastasis 
• In vitro ELISA screening identified 13 active hits that inhibit S100P interaction 
with its extracellular binding target RAGE 
• Synthesis of a short analog series of hit 4 demonstrated proof of concept for 
potential inhibitor design and optimization 
• Active hits reduce in vitro cell invasiveness selectively in S100P-expressing 
pancreatic cancer cells 
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Abstract  
S100P, a calcium- binding protein, is known to advance tumor progression and metastasis in 
pancreatic and several other cancers. Herein is described the in silico identification of a 
putative binding pocket of S100P to identify, synthesize and evaluate novel small molecules 
with the potential to selectively bind S100P and inhibit its activation of cell survival and 
metastatic pathways. The virtual screening of a drug-like database against the S100P model 
led to the identification of over 100 clusters of diverse scaffolds. A representative test set 
identified a number of structurally unrelated hits that inhibit S100P-RAGE interaction, 
measured by ELISA, and reduce in vitro cell invasion selectively in S100P-expressing 
pancreatic cancer cells at 10 µM. This study establishes a proof of concept in the potential 
for rational design of small molecule S100P inhibitors for drug candidate development. 
 
Introduction  
Pancreatic cancer ranks as one of the most lethal cancers in the developed world. In the 
United States alone, it is estimated that during 2020 there will have been 57, 600 diagnoses 
of pancreatic cancer and 47,050 deaths [1], and across Europe, it is estimated the 2018 
disease incidence and mortality were 18.8 and 17.9 per 100,000 population respectively [2].  
Despite the improvements in the survival rates of other cancers, there has been no major 
improvement in the survival rates for pancreatic cancer in the past 40 years, with still only 
around 5% of patients surviving the disease for ten years or more [3]. Pancreatic ductal 
adenocarcinoma (PDAC) represents the majority of pancreatic tumors and has the poorest 
prognosis. 
Lack of early clinical markers and the largely asymptomatic nature of the disease contribute 
to late diagnosis, which is a major factor in the poor survival rate. Consequently, by the time 
of diagnosis, the vast majority of patients have advanced disease, for which 
chemotherapeutic interventions only offer a modest extension of lifespan at best, highlighting 
the urgent need for investigations into new therapies and new drug targets.  
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S100P is a calcium-binding protein that is highly expressed in pancreatic cancer in the early 
stages and in advanced, metastatic disease [4]. There has been much interest in its potential 
use as a prognostic or diagnostic marker [5-8].  S100P has been shown to promote 
progression and metastasis in in vivo models of PDAC [9, 10] and correlates with poor 
patient prognosis. S100P has also been reported in several other cancers, including colon, 
breast, lung, ovarian, nasopharyngeal and cervical cancers [11]. S100P binds the receptor 
for advanced glycation end-products (RAGE) extracellularly [12] and has a number of 
intracellular binding targets, including ezrin-palladin, integrin a7 and the not yet fully 
characterized S100P binding partner (S100PBP) [13], promoting a number of pathways for 
cell survival, proliferation, migration, and invasion [11].  
The protein has shown some promise as a druggable target, with S100P’s cancer-promoting 
effects being suppressed through siRNA silencing [9] and small molecule downregulation of 
S100P expression [14]. Direct inhibition of S100P function has been achieved by use of a 
monoclonal antibody [15] and with the anti-allergy drug cromolyn 1 [16], indicating the 
possibility for the development of small molecules to directly target S100P. Cromolyn has 
been shown to bind to S100P and inhibit its binding to RAGE in vitro. It has also been shown 
to reduce metastatic load and to enhance sensitivity to the standard chemotherapeutic agent 
gemcitabine in vivo [16]. Cromolyn is, however, not likely to be a viable chemotherapeutic 
agent due to its low potency, lack of selectivity and low bioavailability. A series of cromolyn 
analogs have demonstrated some increased potency [17]. However, to date there has not 
been any reported progress in developing more potent and selective “drug-like” small 
molecule inhibitors of S100P, unrelated to cromolyn. 
Virtual screening is an in silico methodology used in drug discovery and development 
projects to streamline and optimise candidate selection. It achieves this by exploiting 
computational models and algorithms which aim to accurately predict which molecules are 
likely to bind well to a biological target of therapeutic interest (and hence elicit an appropriate 
therapeutic response) [18-20] 
Two experimental structures of S100P exist in the RCSB Protein Data Bank (PDB) as an X-
ray crystal structure (PDB Accession Code 1J55) and an NMR ensemble (PDB Accession 
code 1OZO). The former is resolved as a 2 Å monomer with bound calcium ions but with 
residues 46-51 and 95 missing [21]. The NMR ensemble on the other hand contains 16 
conformers that exist as dimers but with no bound calcium ions [22]. There are also three 
mutations in the ensemble compared to the native protein; T6→A, C85→S, and A92→T.  
Using the available experimental information on cromolyn binding and the experimental 
S100P structures, this study employed in silico methods to identify potential binding pockets 
in the NMR ensemble of S100P, which could accommodate cromolyn, and to generate a 
pharmacophore model for S100P. 
Subsequent virtual screening of lead-like databases identified hits – structurally distinct from 
cromolyn – that show promise as inhibitors of S100P’s tumor-promoting mechanisms and 
therefore potentially as chemotherapeutic agents for PDAC. Here, we report our generated 
pharmacophore, the results of the virtual screening of drug-like databases and the effects of 
selected hit compounds in protein and cell-based assays of S100P inhibition, and the 
associated functional effects.  
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Results and Discussion 
In silico modelling and virtual screening 
Conformer number 15 in the NMR ensemble of S100P (1OZO) was identified as the most 
suitable structure for beginning drug discovery studies. Four different pocket detecting 
algorithms – Fpocket [23], Pocket-Finder [24], Q-SiteFinder [25] and MOE Site-Finder 
(Chemical Computing Group Inc.) [26] – independently identified a pocket at the S100P 
dimeric interface of this conformer that was large enough to bind cromolyn. This model 
coincidentally happens to be most representative model of 1OZO according to the authors 
who resolved the NMR ensemble [19]. The residues making up the pocket were located on 
both chains of the homodimer. Limitations of the pocket detection algorithms resulted in the 
pocket at the dimeric interface being resolved as two separate binding sites. The larger of 
the two pockets has a volume of 349 Å3 (Q-SiteFinder) with residues M1, T2, E5, T6, M8, 
G9, I12, F71, S72, and I75 from chain A, and F44, V78, A79, A80, I81, T82, S83, A84, C85, 
H86, K87, Y88, F89, K91, A92, G93, L94, and K95 from chain B contributing to the pocket 
surface. The smaller pocket is more buried than the first and has a volume of 198 Å3 with 
residues G9, I11, I12, D13, F15, S16, S19, S21, Q26, F71, S72, F74, I75, and V78 from 
chain A, and T82 and H86 from chain B contributing to the pocket surface (Figure 1). F15, 
Y88 and F89 are involved in the hydrophobic core of S100P which, is exposed when the 
protein undergoes a conformational change upon calcium-ion binding [27]. The same 
pockets identified by the other programs were found to be sub-sets of those identified by Q-
SiteFinder. In MOE Site-Finder, where identified cavities are ranked according to their 
propensity for ligand binding (PLB) score [28], the pockets identified at the dimeric interface 
were ranked in the top three with respect to propensity for ligand binding. In contrast to other 
published work on S100P-cromolyn interaction using the monomeric crystal structure, where 
it was reported that identified pockets on the protein were symmetrical [29], this was not 
observed in our study. Indeed, none of the pockets identified on the structures in the NMR 
ensemble show symmetricity. However, residues E5, D13, F44, Y88 and F89 of S100P that 
were previously identified to play a vital role in RAGE binding [30] were also identified in our 
pockets. Of note was the fact that the mutated residue A92 was present in the putative 
binding site identified by the independent pocket detection algorithms. To account for this, 
the structure was modified to return it to its native sequence.  The effects of restoring the 
native amino acids on the structure was modeled by in silico site-directed mutagenesis and 
rotamer orientation optimization. There was no significant change to the binding pocket as a 
consequence of this. 
When cromolyn 1 was docked into these pockets (Figure 1B) using the Dock tool in MOE, 
the pose with the most interactions with the protein – three in total – had an estimated 
binding affinity energy score (S) of -10.54 kcal/mol. This pose had two hydrogen bond-
interactions between the carboxylate oxygen at one end of the ligand and residue H86, and 
between the carboxylate oxygen at the other end with residue C85. The third interaction 
involved a pi-stacking hydrophobic interaction between residue F89 and one of the chromen-
4-one moieties of the ligand (Figure 1C).  
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         A             B     C 
 
Figure 1: S100P interaction with cromolyn 1. A: Two overlapping pockets identified at the 
dimeric interface of the protein (monomers in orange/pink) rendered with dummy atoms in 
MOE. B: Cromolyn (space-filling model) docked into pockets. C: Predicted binding 
interactions between cromolyn and S100P. 
 
These interactions served as the basis for the development of a final three-point 
pharmacophore model that was used in a virtual screen of lead-like databases in the MOE 
library. Combined, these databases had 653,214 compounds and the virtual screen returned 
4,619 hits – 0.71% of the databases. ChemAxon’s Library MCS clustering tool (JChem 5.9.0, 
2013) available from ChemAxon (http://www.chemaxon.com) was used to cluster the hits 
based on their chemical similarity. There were 129 clusters with 24 singletons. The hit with 
the most negative binding affinity energy score (S) was selected from each cluster to give a 
diverse collection of hits with low energy scores. From this selection of 153 structures, a total 
of 68 representative database compounds were purchased, these being readily available 
from their commercial suppliers.  
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Initial biological screening of computational hits 
The purchased computational screening hits were subjected to initial biological testing for 
inhibition of S100P-RAGE binding (ELISA), with cromolyn as positive control, using an 
adaptation of the reported ELISA for S100 family members [31]. 
As expected, cromolyn inhibited S100P-RAGE binding at 100nM and above in this assay, 
although it exhibited a maximum inhibition of only 56%, therefore a reliable estimate of IC50 
could not be determined. Thirteen of the 68 diverse scaffolds tested (2-14, Table 1) exhibited 
significant activity in the ELISA at a concentration of 100 nM or lower. Estimated IC50 values 
were calculated where sufficient % inhibition was observed in the assayed concentration 
range. 
 
Table 1: Active hits, with estimated IC50 values, from virtual screening of the pharmacophore 
derived from the putative binding site of cromolyn, 1, against MOE databases 
Compound Vendor ID Structure 
Estimated IC50 
/ nM 
 
2 ChemBridge 
7971920 
 
 
ND 
 
3 
 
ChemBridge 
7230553 
 
 
0.514 
8 
 
 
             4 
 
ChemBridge 
7356270 
 
 
22.7 
 
5 
 
ChemBridge 
7926943 
 
 
0.600 
 
6 
 
Asinex 
ASN 06747799 
 
 
0.555 
 
7 
 
Pharmex 
PHAR058776 
 
 
19.0 
 
8 
Pharmex 
PHAR087402 
 
 
ND 
9 
 
ND: not determined as maximum % inhibition insufficient to determine IC50. 
 
 
 
9 
InterBioScreen 
STOCK2S-
82643 
 
 
7.70 
 
10 
InterBioScreen 
STOCK5S-
26863  
42.6 
 
11 
InterBioScreen 
STOCK5S-
43994  
6.89 
 
12 
InterBioScreen 
STOCK5S-
58409 
 
 
264 
 
13 
InterBioScreen 
STOCK5S-
59895 
  
126 
 
14 
InterBioScreen 
STOCK5S-
33478 
 
77.0 
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Figure 2: Effects of compounds 1-14 on S100P binding to RAGE. Human S100P (2 µM) coated 
wells were incubated with increasing concentrations of the compound tested, in triplicate, and 
exposed to human RAGE-Fc (100nM) followed by goat anti-human secondary antibody to detect 
RAGE bound S100P. Data are compared to S100P/RAGE binding with no inhibitor (DMSO, 100%) 
and are presented as mean ± SEM; data is significant by one way ANOVA, where * = p <0.05, **=p 
<0.01 and *** = p<0.001; n = 9 from 3 plates. 
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Figure 3: Compound 4 (A) and cromolyn 1 (B) block S100P binding to RAGE in a dose dependent 
manner. Human S100P (2 µM) coated wells were incubated with increasing concentrations of the 
compound tested, and exposed to human RAGE-Fc (100nM) followed by goat anti-human secondary 
antibody to detect RAGE bound S100P. Data are compared to S100P/RAGE binding with no inhibitor 
(untreated, 100%) and 0.001% DMSO control (DMSO) and are presented as mean ± SEM; data is 
significant by one way ANOVA, where **=p <0.01 and *** = p<0.001; significance by Dunnett’s 
Multiple comparison post-hoc test is expressed as f = p<0.05, ff =p<0.01 and fff= p<0.001 compared 
to vehicle control (0.001 % DMSO); n=12 from 4 plates.  
 
In the first screening round, compound 4 (ChemBridge Corp., San Diego, ID 7356270) 
exhibited an increased potency compared to cromolyn and significantly prevented S100P-
RAGE interaction in a concentration-dependent manner at ≥10 nM (Figure 3). Compound 4 
has a molecular weight of 440 and cLogP of 2.80, which we considered a suitable starting 
point for analog synthesis, whilst retaining drug-like parameters (mol. wt. ≤500, cLogP ≤5.0); 
this structure was therefore selected as the first hit for further analog development.  
 
 
 
Hit 4 analog synthesis 
Synthesis of compound 4 and a small series of analogs (4a-4y) was carried out using 
adaptations of published methods [32, 33] (Scheme 1). From redocking of this hit it was 
decided to develop the library from solely 3- and 4- substituted anilines to explore the 
expected pharmacophore interactions, as ortho-substituents were a poorer fit for the pocket 
and the rotational restriction introduced could introduce a mixture of rotamers, as has been 
previously reported [34]. The series was designed to provide initial proof of concept that hits 
from the virtual screening could provide a valid scaffold for further hit-to-lead development 
[35].  
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Scheme 1: synthesis of analogs of screening hit 4. 
A total of six analogs significantly inhibited S100P-RAGE interaction at or below 100 nM (4a, 
4b, 4f, 4o, 4r, 4u), with others exhibiting weaker effects.  
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Table 2: Initial analog series from hit compound 4 
Compound X R R' 
Yield from 
16a/b, % 
ELISA 
inhibition  
Estimated 
IC50 / nM 
4 NO2 CO2H H 80 10nM** 22.7 
4a NO2 CO2Et H 84 100 nM *** 13.9 
4b NO2 F H 81 100 nM* ND 
4c NO2 Cl H 82 -  
4d NO2 NO2 H 93 -  
4e NO2 H H 72 -  
4f NO2 H CO2H 80 <10 nM*** 0.482 
4g NO2 H CO2Et 78 -  
4h NO2 H F 88 -  
4i NO2 H Cl 91 -  
4j NO2 H NO2 78 -  
4k NO2 H I 84 -  
4l NO2 H t-Bu 82 -  
4m H CO2H H 95 -  
4n H CO2Et H 96 -  
4o H F H 87 10 nM* 1.30 
4p H Cl H 92 -  
4q H NO2 H 95 -  
4r H H H 83 10 nM* 0.796 
4s H H CO2H 86 -  
4t H H CO2Et 92 -  
4u H H F 96 10 nM* 4.15 
4v H H Cl 94 -  
4w H H NO2 83 -  
4x H H I 89 -  
4y H H t-Bu 93 -  
Statistical significance by one-way ANOVA, * = p <0.05, ** = p < 0.01, *** = p < 0.001,  
- = no significant inhibition below 1 µM, ND = not determined  
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Selected positive hits from the assay (defined as those with significant reduction in S100P-
RAGE binding at ≤1μM) were then taken forward for cell functional assays. All compounds 
maintained solubility in 1% or 0.1% aqueous DMSO at the concentrations used in the 
assays.  
 
Cell functional assays 
Effects of compounds on cell viability 
To rule out general non-specific cytotoxicity or effects not specific to S100P-expressing cells, 
the effects on cell viability of five of the most active library compounds, 3-7, plus the six 
analogs 4a, 4b, 4f, 4o, 4r and 4u, were assessed. Metabolic activity and 
cytotoxicity/cytolysis were measured with the MTS (CellTiter® 96 AQueous One Solution 
assay, Promega) and LDH release (CytoTox-ONE™ Homogeneous Membrane Integrity 
assay, Promega) assays respectively, in S100P-expressing (BxPC-3) and S100P-negative 
(Panc-1) cell lines, at a compound concentration of 10 μM. Cromolyn was used as a positive 
control.  
Samples were normalized to untreated cells. Viability and cytotoxicity were determined in 
comparison to the untreated control. Results indicate that the hit compounds have no 
significant effect on cell metabolic activity in either cell line, as measured by the MTS screen, 
compared to vehicle control (1% DMSO), over 3 days of incubation (Figure 4A, 4B).  
In a similar manner, data indicated that neither the hit compounds nor cromolyn exhibited 
cytotoxicity (measured via LDH release) over three days incubation in either cell-line, when 
compared to vehicle control (Supplementary Data).  
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Figure 4A: Effect of compounds on cell metabolic activity; 105 BxPC-3 cells were exposed to 10µM hit 
compounds for 24 hours, and the effect on MTS staining for each time point measured by absorbance 
at 492nm. Background media absorbance was subtracted from all values and expressed as a 
proportion of untreated cells. Data is expressed as mean ± SEM; data do not show any significant 
differences by two-way ANOVA; n=3 separate experiments. 
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Figure 4B: Effect of compounds on cell metabolic activity of Panc-1 cells; 105 Panc-1 cells were 
exposed to 10 µM hit compounds for 24 hours, and the effect on MTS staining for each time point 
measured by absorbance at 492nm. Background absorbance of media was subtracted from all values 
and expressed as a proportion of untreated cells. Data is expressed as mean ± SEM; data do not 
show any significant differences by two-way ANOVA; n=3 separate experiments. 
 
 
Effects of compounds on cell invasion 
The pro-metastatic effects promoted by S100P include an increase in cell migration and 
invasiveness. The effect of the S100P-binding hit compounds to inhibit cell invasion in 
S100P-expressing cells in vitro was measured via a Transwell invasion assay. In this assay, 
cells invade through the matrigel on upper Transwell chamber towards a lower chamber 
containing a chemoattractant. The results are shown in Figure 5.  
BxPC-3 cells (S100P-positive) exhibit a high invasiveness, as shown by the difference 
between negative control (no chemoattractant) and positive control (with chemoattractant). 
The vehicle control lacked any effect in blocking cell invasion, yet all of the selected ELISA-
positive hit compounds were able to significantly (p < 0.001) inhibit invasion to the lower 
chamber at a concentration of 10 µM. In this model, 10 µM cromolyn did not exhibit a 
statistically significant effect, although significant inhibition was observed at ≥100 µM. In 
comparison, Panc-1 cells, lacking S100P expression, exhibited a lower invasive trait, which 
was not significantly inhibited by any of the hit compounds. 
Therefore, the observed reduction in cell invasiveness is consistent with an S100P-specific 
inhibitory effect. 
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Figure 5: The invasive capacity of BxPC-3 and Panc-1 cells treated with 10 µM of compound 4 for 48 
h. A) Invasion of BxPC-3 treated cells towards 10 % FBS as a chemoattractant. B) Invasion of Panc-1 
treated cells towards 10 % FBS as a chemoattractant. C) Graphical representation of the data showing 
a comparison between the invasions of BxPC-3 and Panc-1 treated cells and controls. The total number 
of invading cells in the lower chamber was determined by counting the number of cells in 5 different 
fields, at 100x magnification. Error bars represent the mean ± standard error from three independent 
invasion experiments (n=3; each containing average of 5 picture fields selected at x100 total 
magnification).  
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Figure 6:  Transwell® invasion assay of A: BxPC-3 and B: Panc-1 cells treated with 10 μM hit 
compounds or cromolyn (10, 100, 200 μM); data are shown as the number of cells that have invaded 
through the matrix to the lower chamber. Data is shown as mean ± SEM number of invasive cells as 
counted under the microscope (x100). Significant difference between groups by one way ANOVA p 
<0.001; Bonferroni’s post hoc test between cells exposed to chemoattractant (untreated) and DMSO 
(vehicle control, 0.001 % DMSO) or cell exposed to hit compounds is indicated by * = p<0.05, ** = 
p<0.01 and *** = p<0.001; n = 10-15 observations from 3 separate experiments. N.B. Cromolyn 
exhibited significant inhibition of invasion at concentrations ≥100 μM. 
Total protein content of invasive cells was measured by the BCA assay to confirm the 
reduced level of cells present.  (Supplementary Data)  
In order to exclude any possibility that reduced cell invasiveness was due to cell death 
during the time period of the assay, the viability of cells in the upper Transwell® chamber 
was assessed via measurement of LDH release. There was no significant increase in LDH 
release for either cell line after treatment with hit compounds or cromolyn. (Supplementary 
Data).  
 
Conclusions 
The model of the putative small molecule binding pocket of S100P, based upon the NMR 
structure of the apo-protein, has successfully led to identification of several new “drug-like” 
small molecule inhibitors of the S100P-RAGE interaction and S100P-mediated cell invasion 
in vitro. The compounds identified in this study represent a diverse set of scaffolds, providing 
proof of concept of the wider potential to design novel small molecule therapies that will have 
a functional and selective effect against S100P-expressing cancers. S100P inhibitors have 
potential to reduce metastatic spread and to be deployed in a combination therapy to 
improve the efficacy of standard chemotherapeutic treatments. There is an urgency in the 
search for therapeutic agents against pancreatic cancer, particularly in the management of 
advanced disease, which comprises the majority of new diagnoses. Therefore, this 
represents an exciting advance in the search for a targeted, novel therapy for PDAC and 
other S100P-expressing cancers.  
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Experimental 
In silico modeling  
Preparation of Experimental Protein Structures  
The X-ray crystal structure of monomeric calcium bound S100P (1J55) was extracted from 
the PDB. The homodimer was generated from the deposited coordinates using the UCSF 
Chimera package [33]. Having generated the dimer all water molecules were removed from 
the structure. The NMR ensemble of S100P (1OZO) contains sixteen different conformations 
of homodimeric S100P. The ensemble was downloaded from the PDB website and the 
conformers were separated by copying their coordinates into Microsoft WordPad and saving 
as individual PDB files. 
Identification of Potential Binding Pockets  
Four complementary, yet independent, cavity detection algorithms were used to identify 
putative binding pockets at the dimeric interface for the experimental protein structures. A 
consensus approach was employed to minimise bias from a single pocket-detection 
algorithm, and hence identify the most credible cavities (i.e. those that spanned the dimeric 
interface of the protein and had sufficiently large volumes to accommodate cromolyn) for 
further study. The four algorithms used were: 
FPocket [23] (obtained from http://bioserv.rpbs.univ-paris-diderot.fr/cgi-bin/fpocket, currently 
available from https://github.com/Discngine/fpocket),  
Pocket-Finder [24] (obtained from http://www.modelling.leeds.ac.uk/pocketfinder/),  
Q-Site Finder [25] (obtained from http://www.modelling.leeds.ac.uk/qsitefinder/ ) and  
MOE Site Finder [26, 37].  
MOE SiteFinder algorithms used hypothetical hydrophilic probes of 1.4Å radius, hypothetical 
hydrophobic probes of 1.8Å and rejection criteria that excluded hydrophilic spheres with no 
hydrophobic alpha sphere within a radius of 3Å. 
In silico site-directed mutagenesis, and localised rotamer optimization, was carried out using 
the MOE software to return any mutated residues in the S100P NMR ensemble structures 
back to the native sequence.  
Docking Studies – Interaction of Cromolyn at the S100P Dimeric Interface 
The Dock algorithm in MOE was used to investigate the interactions between cromolyn and 
the putative binding pockets at the S100P dimeric interface. The cromolyn molecule was 
generated and minimised using the Molecule Builder application in MOE. Ionisation states at 
pH 7.4 were determined for cromolyn using the molecule washing function. The S100P 
protein file was protonated using Protonate 3D. The potential binding site identified at the 
dimeric interface using the pocket detection algorithms were recreated by selecting 
appropriate residues from the protein using the Sequence Editor Window and a surface map 
to be used in the docking was generated using a cut-off radius of 4.5 Å from the selected 
residues.  The rotate bond option was switched on to allow different conformations of the 
cromolyn ligand to be examined during the docking run. The placement method used was 
triangle matcher, and the rescoring 1 function selected was London dG. Energy minimisation 
of the docked poses in the protein was carried out using the default Forcefield option in the 
Refinement dialogue box. The second refinement scoring function was set to “None”, which 
means that the final refined poses are ranked according to an MM/GBVI binding free energy 
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estimate. Fifty poses were retained for each docking, and duplicate poses were removed 
from the analysis. The online server Ballaxy [38] was used to rescore high-ranked poses in 
an effort to eliminate scoring function bias. Any poses not re-scored highly were removed 
from further analysis. 
Pharmacophore Generation and Validation 
Pharmacophores were generated using the Pharmacophore Query Editor in MOE based on 
the results of the docking studies. Pharmacophore features highlighted by annotation points 
were selected in both the protein and the ligand. Default radii suggested by the 
Pharmacophore Query Editor were used. This gave rise to a four-point pharmacophore 
comprising an aromatic feature (Aro) and three anionic acceptor (Ani&Acc) interactions 
(Figure 6). This pharmacophore was employed in the virtual screening of the 
MOE lead-like database but matched only 52 of the 653,214 compounds (0.008% hit rate) in 
the database (Table 2). This includes partial matches whereby three of the four 
pharmacophoric features were satisfied. It is possible for a single 
carboxylic acid moiety to satisfy two anionic acceptor features of the pharmacophore 
simultaneously (although in reality only one such H-bond interaction can occur at a time 
upon ligand-receptor binding), and hence the minimum number of an H-bond acceptors 
required for a hit to be considered a match from the virtual screening studies was one. 
The four-point pharmacophore was very stringent. The distances between pharmacophoric 
features mean that any compounds returned by virtual screening would need to be relatively 
large. This coupled with the need for at least two acidic groups in each molecule to fulfil the 
anionic acceptor requirements explains the relatively low hit rate observed. In order to 
improve the hit-rate and increase the chemical diversity of the compounds identified by 
virtual screening, the pharmacophoric constraints were relaxed to reduce the number of 
constraints and modify the nature of the anionic acceptor requirement. By relaxing the 
constraints in terms of both the number of features that needed to be fulfilled and the type 
of acceptor functionality in the ligand, a three-point pharmacophore query was obtained that 
spanned the putative dimeric interface and consisted of two hydrogen bond acceptor 
features, and a hydrophobic feature.  
The number of hits returned by the virtual screen with the relaxed pharmacophore was 
increased almost 100-fold (4619 hits, 0.71% hit rate). Cromolyn was seeded into the MOE-
lead like database and was returned as a high-ranking hit using the refined pharmacophore. 
This gave some confidence that the tool was appropriately selective. It was not possible to 
validate the pharmacophore further, given that at the time of the study only cromolyn, and 
structurally similar derivatives, were shown to have activity against S100P. Hence, there was 
a paucity of molecules with known biological activities against S100P which could be used to 
further validate the pharmacophore. 
Screening Database Curation and Filtering 
The ‘lead-like’ compound from the ZINC database and the internal MOE screening database 
were used in the screen. Compounds from the ZINC database were imported into MOE as 
SMILES, converted into 3D molecules and “washed and filtered” prior to virtual screening 
taking place. This stage filtered out compounds with a molecular weight of >600, those 
compounds where the sum of hydrogen bond donors plus hydrogen bond acceptors was 
>12, those with more than seven rotatable bonds, those compounds with more than 4 chiral 
centres, compounds with more than 8 rings and any d-hybrid compounds. 
Tanimoto coefficients were calculated for all remaining compounds in the database and one 
compound from those with pairwise values of 0.7 or greater was removed to ensure that a 
structurally diverse database, representative of lead-like chemical space but with the 
smallest number of compounds possible was created. These compounds were screened 
against the pharmacophores generated in the previous step. 
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Hit clustering 
Those compounds matching the pharmacophore were then clustered according to chemical 
structure using the ChemAxon software. The clustering employed was hierarchical, used a 
Maximum Common Substructure (MCS) value of 9 and used default matching parameters of 
all atom types, bond types, whole rings and charge. Medoids were identified from each 
cluster as potential compounds to take forward (subject to availability and resource) into the 
biological screening experiments. 
 
General chemistry 
Reagents for the chemical synthesis, unless specified otherwise, and anhydrous solvents 
were purchased from Sigma-Aldrich (Gillingham, Dorset, UK) and were used without further 
purification. All other solvents were purchased from Thermo Fisher Scientific 
(Loughborough, UK). Where necessary, solvents were dried using activated 3 Å (methanol, 
ethanol, dichloromethane) and 4 Å (diethyl ether) molecular sieves. 1H-NMR and 13C-NMR 
spectra were recorded on a JEOL ECA/54/SSS (400 or 600 MHz) spectrometer using TMS 
or residual solvent as internal standard. Deuterated solvents used for compound analysis 
are indicated with individual compound data. Raw NMR data files were processed with JEOL 
Delta 5.3.1. Chemical shifts are given in ppm relative to tetramethylsilane and J values 
(where given) are in Hz.  Infrared spectra were recorded on a Scimitar 800 FT-IR 
spectrometer (Varian Inc.), a Nicolet 6700 FT-IR Smart iTR (Thermo Scientific) spectrometer 
using a Golden GateTM Diamond ATR adapter, or a Perkin Elmer FT-IR/FIR Spectrometer 
Frontier (Version 10.03.07), with samples prepared as thin films on the universal ATR 
sampling accessory.  Liquid chromatography–mass spectrometry (LC-MS) was performed 
using a Varian 1200L Quadrupole LC/MS/MS system equipped with Electrospray Ionisation 
(ESI) (Agilent Technologies, USA) in positive and negative ionisation modes and using a 
Varian Pursuit 50 mm x 4.6 mm 5 micron pore size C18 reverse phase column. Thin-layer 
chromatography (TLC) was carried out using Macherey-Nagel 60 Å (250 μm thick) flexible 
polyester sheet silica gel plates pre-coated with fluorescent indicator UV254. 
Dichloromethane was used as the mobile phase unless otherwise stated. Column 
chromatography was carried out using silica gel (high-purity grade, pore size 60 Å, 230-400 
mesh particle size, 40-63 μm particle size, for flash chromatography, Sigma-Aldrich, 
Gillingham, Dorset, UK). Melting points were measured in open capillaries using a Griffin 
melting point apparatus and are uncorrected.  
Synthesis of analogs of 4 
Dihydroanthracene Diels-Alder adducts 16a, 16b 
Maleic anhydride (1.00g, 10 mmol) was added to a stirred solution of anthracene (10 mmol 
mmol) in xylene (25 mL) and the mixture heated under reflux at 140-143 °C until all the 
diene disappeared, as indicated by TLC (3-72 h) [32]. The reaction mixture was cooled to 
room temperature before placing on ice with stirring. A precipitate separated out upon 
cooling, which was filtered, washed with ice-cold xylene and dried under suction to give the 
desired Diels-Alder cycloadduct as a pale-yellow powder which was used in the next step 
without further purification.  
9-nitro-9,10-dihydro-9,10-[3,4]furanoanthracene-12,14-dione (16a) 
Yield 65 %; mp. 239-240 °C (lit. 244-245 °C [32]); 1H-NMR (600 MHz, DMSO-d6) δ (ppm) 
7.67 (1 H, m), 7.50 - 7.58 (2 H, m), 7.44 - 7.37 (3 H, m,), 7.37 - 7.32 (1 H, m), 7.05 (1 H, dd, 
J = 7.5, 0.5 Hz), 5.11 (1 H, d, J = 3.0 Hz), 4.66 (1 H, d, J = 9.3 Hz), 3.94 (1 H, dd, J = 9.3, 
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3.2 Hz); 13C-NMR (150 MHz, DMSO-d6) δ (ppm) 170.32, 168.99, 139.47, 137.17, 136.93, 
134.15, 129.49, 129.44, 128.40, 128.17, 126.11, 125.60, 123.37, 120.81, 93.24, 51.14, 
49.25, 44.79; IR max/cm-1: 2988, 2969, 1781, 1556, 1361; MS (ESI) found m/z 322.3 [M 
+H]+, C18H11NO5 calculated 321.1.  
 
9,10-dihydro-9,10-[3,4]furanoanthracene-12,14-dione (16b) 
Yield 92%, mp. 259-260 °C (lit. 261-263 °C [32]); 1H-NMR (400 MHz, acetone-d6) δ  
(ppm) 7.51 - 7.47 (2 H, m, Ar-CH), 7.38 - 7.33 (2 H, m), 7.17 - 7.22 (4 H, m), 4.91 - 4.89 (2 H, 
m), 3.75 - 3.73 (2 H, m); 13C-NMR (100 MHz, acetone-d6) δ (ppm) 171.22, 141.51, 139.41, 
127.23, 126.79, 125.09, 124.48, 48.24, 45.29; IR max/cm-1: 3077, 3026, 2970, 1782; MS (ESI) 
found m/z 277.1 [M +H]+, C18H12O3 requires 276.3.   
Synthesis of 13-(aryl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-diones (4, 4a-4y)  
Maleic anhydride-anthracene cycloadduct 16a or 16b (0.3-0.5 mmol), and the appropriate 3- 
or 4-substituted aniline (1.2-1.5 eq) were stirred under reflux in glacial acetic acid (10 mL) 
between 1-5 h then cooled to room temperature. De-ionized water (25-40 mL) was added to 
the reaction mixture and the resulting precipitate was filtered, washed with ice-cold de-
ionized water and dried. Recrystallization from glacial acetic acid furnished the products as 
white or cream crystalline solids.  
 
 
3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoic acid (4): 
Yield 80%; mp 271-272 oC;  1H NMR (600 MHz, acetone-d6) δ (ppm) 8.00 - 7.92 (1 H, m), 
7.77 - 7.69 (2 H, m), 7.52 - 7.35 (7 H, m), 7.27 (1 H, dt, J=5.2, 1.7 Hz), 7.13 - 7.06 (1 H, m), 
6.80 - 6.72 (1 H, m), 5.03 (1 H, d, J = 3.1 Hz), 4.58 (1 H, d, J = 8.9 Hz), 3.72 (1 H, dd, J = 
8.9, 3.1 Hz). 13C NMR (150 MHz, DMSO-d6) δ (ppm) 174.22, 173.02, 166.09, 139.36, 
137.06, 136.90, 133.67, 131.79, 131.46, 130.58, 129.50, 129.39, 128.68, 128.38, 127.42, 
127.35, 125.34, 124.84, 123.18, 120.15, 93.18, 49.08, 47.46, 44.72; IR max/cm-1: 3535 (br), 
1705, 1551, 1366; MS (ESI, negative) found m/z: 439.2 [M –H]-, C25H16N2O6 calculated 
440.1. 
 
Ethyl 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoate (4a): 
Yield 84%; mp 202-203 oC;  1H NMR (600 MHz, DMSO-d6)  (ppm) 7.90 (1 H, m), 7.70 (1 H, 
d, J = 7.2 Hz), 7.65 - 7.63 (1H, m), 7.53 - 7.35 (6 H, m), 7.05 (1 H, d, J = 7.2 Hz), 6.99 (1 H, 
t, J = 1.7 Hz), 6.77 - 6.75 (1 H, m), 5.07 (1 H, d, J = 3.1 Hz), 4.49 (1 H, d, J = 8.6 Hz), 4.30 (2 
H, q, J=7.2 Hz), 3.68 (1 H, dd, J = 8.6, 3.1 Hz), 1.32 (3 H, t, J = 7.2 Hz); 13C NMR (150 MHz, 
23 
 
DMSO-d6)  (ppm) 174.22, 173.03, 164.49, 139.28, 137.08, 136.86, 133.68, 131.59, 131.18, 
130.80, 129.67, 129.45, 128.68, 128.38, 127.42, 127.34, 127.21, 125.35, 124.85, 123.19, 
120.15, 93.18, 61.11, 49.12, 47.50, 44.72, 14.07; IR max/cm-1: 2984, 2903 (CH stretch), 
1710 (C=O stretch), 1551 (NO2 asymmetric), 1363 (NO2 symmetric); MS (ESI) found m/z: 
469.3 [M + H]+,. C27H20N2O6 calculated 468.1. 
 
13-(3-fluorophenyl)-9-nitro-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4b):  
Yield 81%; mp 241-243 oC; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.74 (1 H, d, J = 7.6 Hz), 
7.64-7.62 (1 H, m), 7.49-7.47 (1H, m) 7.42-7.34 (5H, m), 7.24-7.20 (1 H, m), 7.05 (1H, d, J = 
7.6 Hz) , 6.33-6.27 (2 H, m),  5.06 (1 H, d,  J= 3.1 Hz), 4.49 (1 H, d, J = 8.9 Hz), 3.56 (1 H, 
dd, J = 8.9, 3.1 Hz); 13C NMR (150 MHz, DMSO-d6) δ (ppm) 174.02, 172.82, 161.56 (d, 
1JC-F 
= 242 Hz), 139.28, 137.07, 136.85, 133.69, 132.56, 130.84, 128.69, 128.41, 127.43, 127.36, 
125.36, 124.85, 123.20, 122.66, 120.16, 115.89 (d, 2JC-F = 20 Hz), 113.69 (d, 
2JC-F = 24 Hz), 
93.17, 49.00, 47.38, 44.72; IR max/cm-1: 3075, 3040, 3015, 2973, 2890, 1706, 1551, 1383; 
MS (ESI) found m/z: 415.0 [M + H]+, C24H15FN2O4 calculated 414.1. 
 
13-(3-chlorophenyl)-9-nitro-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4c):  
Yield 82%; mp 255-230 oC; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.71 (1 H, d, J = 7.2 Hz), 
7.66 - 7.63 (1 H, m), 7.51 - 7.48 (1 H, m), 7.46-7.40 (5 H, m), 7.37 (1 H, td, J = 7.2, 1.8 Hz), 
7.06 (1 H, d, J = 6.9 Hz), 6.48 - 6.46 (1 H, m), 5.08 (1 H, d, J = 3.3 Hz), 4.50 (1 H, d, J = 8.9 
Hz), 3.70 (1 H, dd, J = 8.9, 3.2 Hz);13C NMR (150 MHz, DMSO-d6) δ (ppm) 174.09, 172.91, 
139.27, 137.11, 136.85, 133.71, 133.01, 132.48, 130.82, 128.94, 128.73, 128.42, 127.46, 
127.38, 126.28, 125.41, 125.27, 124.90, 123.24, 120.20, 93.18, 49.07, 47.44, 44.72; IR 
max/cm-1: 3115, 2981, 2966, 1717, 1547, 1383. MS (ESI) found m/z: 431.4 [35Cl M + H]+, 
C24H15ClN2O4 calculated 430.1.  
 
9-nitro-13-(3-nitrophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4d):  
Yield 93%; mp 240-242 oC ; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 8.23 (1 H, m), 7.72 (1 H, 
d, J = 7.2 Hz), 7.70 (1 H, d, J = 7.8 Hz),  7.66 - 7.64 (1 H, m), 7.53 – 7.50 (1 H, m), 7.45-7.41 
(3 H, m), 7.39-7.36 (2 H, m), 7.08 (1 H, d, J = 7.2 Hz), 6.95 (1 H, dd, J = 8.8, 2.1 Hz), 5.11 (1 
H, d, J = 3.0 Hz), 4.53 (1 H, d, J = 8.9 Hz), 3.76 (1 H, dd, J = 8.9, 3.1 Hz); 13C NMR (150 
MHz, CD2Cl2) δ (ppm) 173.55, 172.23, 148.41, 138.77, 136.96, 136.39, 133.86, 132.37, 
132.01, 130.10, 128.96, 128.80, 127.93, 127.76, 125.41, 124.40, 123.93, 123.72, 121.67, 
120.95, 93.42, 49.13, 47.88, 46.04; IR max/cm-1: 3094, 3080, 3049, 2976, 2971, 2959, 2887, 
1709, 1548, 1529, 1341; MS (ESI) found m/z: 442.4 [M + H]+, C24H15N3O6 calculated 441.1.  
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9-nitro-13-phenyl-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4e):  
Yield 72%; mp 110-112 oC ; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.69 (1 H, d, J = 7.2 Hz), 
7.64 - 7.61 (1 H, m), 7.48 - 7.45 (1 H, m), 7.42 - 7.38 (3 H, m), 7.36 - 7.32 (4 H, m), 7.04 (1 
H, d, J = 7.2 Hz), 6.44 - 6.41 (2 H, m), 5.05 (1 H, d, J =3.4 Hz), 4.48 (1 H, d, J = 8.9 Hz), 
3.65 (1 H, dd, J = 8.9, 3.4 Hz); 13C NMR (150 MHz, DMSO-d6) 174.39, 173.17, 139.42, 
137.12, 136.99, 133.72, 131.28, 129.01, 128.81, 128.71, 128.41, 127.44, 127.36, 126.42, 
125.39, 124.86, 123.23, 120.17, 93.21, 48.98, 47.39, 44.73; IR max/cm-1: 3070, 2972, 2903, 
1713, 1550, 1387; MS (ESI) found m/z: 397.5 [M + H]+. C24H16N2O4 calculated 396.1. 
 
4-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoic acid (4f):  
Yield 80%; mp 344-345 oC;  1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.90 (2 H, d, J = 8.4 Hz), 
7.70 (1 H, d, J = 8.4 Hz), 7.64-7.62, (1 H, m), 7.48 - 7.46 (1 H, m), 7.41 - 7.35 (4 H, m), 7.04 
(1 H, d, J = 7.2 Hz), 6.762 (2 H, d, J = 8.4 Hz), 5.07 (1 H, d, J = 3.0 Hz), 4.50 (1 H, d, J = 9.0 
Hz), 3.76 (1 H, dd, J = 9.0, 3.0 Hz); 13C NMR (150 MHz, DMSO-d6) δ (ppm) 174.04, 172.84, 
166.35, 139.33, 137.00, 136.89, 134.87, 133.62, 131.01, 129.92, 128.69, 128.46, 127.41, 
127.40, 126.35, 125.33, 124.84, 123.16, 120.15, 93.18, 49.06, 47.45, 44.72; IR max/cm-1: 
3284 (br), 3076, 2970, 2903, 1702, 1550, 1389. MS (ESI, negative) found m/z: 439.4 [M –H]-
, C25H16N2O6 calculated 440.1.  
 
Ethyl 4-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoate (4g): 
Yield 78%; mp 255-260 oC ; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.94 (2 H, d, J = 8.3 Hz), 
7.71 (1 H, d, J = 7.6 Hz), 7.65-7.63 (1 H, m), 7.51- 7.48 (1 H, m), 7.43 - 7.35 (4 H, m), 7.06 
(1 H, d, J = 6.9 Hz), 6.67 (2 H, d, J = 6.9 Hz), 5.09 (1 H, d, J = 2.8 Hz), 4.51 (1 H, d, J = 8.9 
Hz), 4.30 (2 H, q, J = 6.9 Hz), 3.71 (1 H, dd, J = 8.9, 2.8 Hz), 1.30 (3 H, t, J = 6.9 Hz); 13C 
NMR (150 MHz, DMSO-d6) δ (ppm) 174.05, 172.86, 164.81, 139.32, 137.01, 136.89, 135.20, 
133.63, 130.02, 129.84, 128.73, 128.50, 127.44, 126.54, 125.36, 124.88, 123.18, 120.18, 
93.19, 61.02, 49.09, 47.48, 44.74, 14.08; IR max/cm-1: 2989, 1710, 1550, 1394; MS (ESI) 
found m/z: 469.3 [M + H]+, C27H20N2O6 calculated 468.1.  
 
 
 
13-(4-fluorophenyl)-9-nitro-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4h):  
Yield 88%; mp 223-225 oC ; 1H NMR (600 MHz, DMSO- d6) δ (ppm) 7.71 (1H, d, J = 7.0 Hz), 
7.65 - 7.63 (1H, m), 7.49 - 7.47 (1H, m), 7.44 – 7.35 (4 H, m), 7.23 (2H, t, J = 9.0 Hz), 7.06 
(1H, d, J = 8.4 Hz), 6.50 - 6.47 (2 H, m), 5.07 (1 H, d, J = 3.0 Hz), 4.49 (1 H, d, J = 8.4 Hz), 
3.68 (1 H, dd, J = 8.4, 3.0 Hz). 13C NMR (150 MHz, DMSO- d6) δ (ppm) 174.36, 173.15, 
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161.65 (1JC-F = 242 Hz), 139.37, 137.12, 136.93, 133.72, 128.73, 128.60, 128.55, 128.44, 
127.46, 127.38, 125.38, 124.89, 123.23, 120.19, 116.12 (d, 2JC-F = 23 Hz), 93.20, 48.99, 
47.38, 44.72. IR max/cm-1: 2981, 2970, 2893, 1710, 1551, 1395; MS (ESI) found m/z: 415.5 
[M + H]+, C24H15FN2O4 calculated 414.1. 
 
13-(4-chlorophenyl)-9-nitro-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione  (4i):  
Yield 91%; mp 270-273 oC; 1H NMR (600 MHz, DMSO-) δ (ppm) 7.66 (1 H, d , J = 7.8 Hz), 
7.60 - 7.58 (1 H, m), 7.44 - 7.42 (61 H, m), 7.39 (2 H, d, J = 8.9 Hz). 7.38 – 7.35 (3 H, m), 
7.31 (1 H, dt, J = 7.8, 1.4 Hz), 7.01 (1 H, d, J = 7.2 Hz), 6.47 - 6.45 (2 H, d, J = 8.9 Hz), 5.03 
(1 H, d, J = 3.0 Hz), 4.45 (1 H, d, J = 8.9 Hz), 3.64 (1 H, dd, J = 8.9, 3.0 Hz); 13C NMR (150 
MHz, DMSO- d6) δ (ppm) 174.23, 173.03, 139.36, 137.10, 136.93, 133.70, 133.45, 130.05, 
129.22, 128.77, 128.49, 128.13, 127.50, 127.43, 125.40, 124.91, 123.23, 120.23, 93.22, 
49.07, 47.46, 44.76; IR max/cm-1: 2981, 2971, 2887, 1709, 1551, 1389; MS (ESI) found m/z: 
431.4 [35Cl M + H]+, C24H15ClN2O4 calculated 430.1.  
 
9-nitro-13-(4-nitrophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4j):  
Yield 78%; mp 316-318 oC; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 8.24 (2 H, d, J = 8.4 Hz), 
7.71 (1H, d, J = 7.2 Hz), 7.63 - 7.61 (1 H, m), 7.49 - 7.47 (1 H, m), 7.42 – 7.34 (4 H, m), 7.06 
(1 H, d, J = 7.6 Hz), 6.82 (2 H, d, J = 8.4 Hz), 5.09 (1 H, d, J = 3.0 Hz), 4.52 (1 H, d,  J = 8.8 
Hz), 3.73 (1 H, dd, J = 8.8, 3.0 Hz); 13C NMR (150 MHz, DMSO-d6) δ (ppm) 173.87, 172.65, 
147.01, 139.25, 136.99, 136.82, 136.55, 133.60, 128.77, 128.56, 127.50, 127.32, 125.36, 
124.93, 124.46, 123.16, 120.22, 93.19, 49.16, 47.51, 44.74; IR max/cm-1: 3121, 3087, 2978, 
2855, 1712, 1551, 1521, 1344; LC-MS (ESI) found  m/z: 442.5 [M + H]+, C24H15N3O6 
calculated 441.1.   
 
 
13-(4-iodophenyl)-9-nitro-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4k): 
Yield 84%; mp 305-308 oC; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 7.74 - 7.70 (3H, m), 7.63 
- 7.61 (1H, m), 7.47 - 7.32 (5H, m), 7.05 (1 H, d, J = 7.5 Hz), 6.28 (2 H, d, J = 7.2 Hz), 5.06 
(1 H, d, J = 3.1 Hz), 4.48 (1 H, d,  J= 8.8 Hz), 3.66 (1 H, dd, J = 8.8, 3.1 Hz); 13C NMR (100 
MHz, DMSO-d6) δ (ppm) 174.65, 173.45, 139.89, 138.50, 137.60, 137.47, 134.20, 131.46, 
129.28, 128.91, 127.94, 125.90, 125.41, 123.73, 120.73, 95.62, 93.74, 49.59, 47.97, 45.28; 
IR max/cm-1: 2968, 2901, 1706, 1550, 1387; MS (ESI) found m/z: 523.3 [M + H]+, 
C24H15IN2O4 calculated 522.0. 
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13-(4-(tert-butyl)phenyl)-9-nitro-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione 
(4l):  
Yield 82%; mp 238-240 oC ; 1H NMR (400 MHz, CD2Cl2) δ (ppm) 7.75 - 7.72 (1 H, m), 7.55 - 
7.52 (1 H, m), 7.43 - 7.28 (9 H, m), 7.12 - 7.09 (1 H, d, J = 7.6 Hz), 6.38 (2 H, d, J = 7.9 Hz), 
4.92 (1 H, d, J = 3.1 Hz), 4.43 (1 H, d, J = 9.0 Hz), 3.53 (1 H, dd, J = 9.0, 3.1 Hz), 1.26 (9 H, 
s). 13C NMR (150 MHz, CD2Cl2) δ (ppm) 174.34, 172.92, 152.38, 139.09, 137.23, 136.57, 
133.95, 128.82, 128.58, 128.42, 127.72, 127.61, 126.18, 125.90, 125.37, 124.34, 123.89, 
120.86, 93.47, 48.98, 47.74, 45.97, 34.65, 30.92; IR max/cm-1: 2981, 2902, 2875, 1714, 
1547, 1392; MS (ESI) found m/z: 453.5 [M + H]+, C28H24N2O4 calculated 452.2.  
 
 
3-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoic acid  (4m): 
Yield 95%; mp 285-288 oC (lit. 288-290 °C [39]) ; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.89 
- 7.87 (1 H, m), 7.53 – 7.51 (2 H, m), 7.48 (1 H, t, J = 7.8 Hz), 7.33 - 7.31 (2 H, m), 7.22-7.20 
(4 H, m), 7.10 (1 H, m) 6.68 (1 H, d, J  = 8.4 Hz), 4.88 (2 H, s), 3.44 (2 H, s).; 13C NMR (150 
MHz, DMSO-d6) δ (ppm) 175.86, 166.26, 141.59, 139.25, 132.01, 131.81, 130.71, 129.24, 
127.50, 126.67, 126.39, 124.79, 124.40, 46.77, 44.85; IR max/cm-1: 3321, 1704, 1594, 1385; 
MS (ESI, negative) found m/z:394.2 [M –H]-, C25H17NO4 calculated 395.1. 
 
Ethyl 3-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoate  (4n): 
Yield 96%; mp 205-207 oC ; 1H NMR (400 MHz, acetone-d6) δ (ppm) 7.93 (1 H, d, J = 7.8 
Hz), 7.53 - 7.50 (2 H, m), 7.45 (1 H, t, J = 7.9 Hz), 7.37 - 7.30 (2 H, m), 7.26 - 7.16 (5 H, m), 
6.80- 6.77 (1 H, m), 4.89 (2 H, s), 4.33 (2 H, q, J = 7.1 Hz), 3.47 (2 H, s), 1.36 (3 H, t, J = 7.1 
Hz); 13C NMR (150 MHz, acetone-d6) δ (ppm) 175.63, 164.90, 141.95, 139.66, 132.81, 
131.39, 131.29, 129.12, 129.02, 127.83, 126.84, 126.61, 125.01, 124.37, 60.94, 47.24, 
45.81, 13.73; IR max/cm-1: 3070, 3042, 2992, 1718, 1703; MS (ESI) found m/z: 424.4 [M + 
H]+, C27H21NO4 calculated 423.2.  
 
13-(3-fluorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4o): 
Yield 87%; mp 228-230 oC ; 1H NMR (400 MHz, CD2Cl2) δ (ppm) 7.46 - 7.41 (2 H, m), 7.35 - 
7.17 (7 H, m), 7.05 – 6.97 (1 H, m), 6.33 (1 H, d, J = 7.6 Hz), 6.24 (1 H, dt, J = 9.2, 2.2 Hz), 
4.87 - 4.86 (2 H, m), 3.39 - 3.38 (2 H, m); 13C NMR (100 MHz, CD2Cl2) δ (ppm) 175.67, 
162.44 (d, 1JC-F = 245 Hz), 141.38, 139.00, 133.08, 133.00 (d, 3JC-F = 10 Hz), 130.30 (d, 3JC-F 
= 10 Hz), 127.20, 126.84, 125.08, 124.41, 122.44, 115.76 (d, 2JC-F = 21 Hz), 114.05 (d, 2JC-F 
= 24 Hz), 47.13, 45.89; IR max/cm-1: 3083, 3041, 3020, 2974, 1702; MS (ESI) found m/z: 
370.4 [M + H]+, C24H16FNO2 calculated 369.1.  
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13-(3-chlorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4p): 
Yield 92%; mp 238-240 oC; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.52 - 7.50 (2 H, m), 7.43 
- 7.37 (2 H, m), 7.34 - 7.30 (2 H, m), 7.24 - 7.19 (4 H, m), 6.48 - 6.49 (2 H, m), 4.88 (2 H, s), 
3.43 (2 H, m); 13C NMR (150 MHz, DMSO-d6) δ (ppm) 175.69, 141.48, 139.29, 133.07, 
132.90, 130.65, 128.58, 126.66, 126.42, 125.40, 124.82, 124.42, 46.72, 44.86; IR max/cm-1: 
3077, 2960, 1708; MS (ESI) found m/z: 386.3 [35Cl M + H]+, C24H16ClNO2 calculated 385.1. 
 
13-(3-nitrophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4q): 
Yield 95%; mp 282-285 oC (lit. 248 °C [39]); 1H NMR (400 MHz, CD2Cl2) δ (ppm) 8.15 - 8.11 
(1 H, m), 7.52 - 7.42 (3 H, m), 7.38 - 7.31 (3 H, m), 7.27 - 7.19 (4 H, m), 6.92 (1 H, m), 4.88 
(2 H, s), 3.43 (2 H, s); 13C NMR (150 MHz, CD2Cl2) δ (ppm) 175.41, 148.40, 141.19, 138.89, 
132.65, 132.54, 129.91, 127.30, 126.90, 125.09, 124.41, 123.36, 121.77, 47.21, 45.93; IR 
max/cm-1: 3081, 3048, 3011, 2957, 1710, 1530, 1341; MS (ESI) found m/z: 397.4 [M + H]+, 
C24H16N2O4 calculated 396.1. 
 
13-phenyl-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4r): 
Yield 83%; mp 211-215 oC ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 7.52-7.50 (2 H, m), 7.36 
- 7.28 (5 H, m), 7.23-7.19 (4 H, m), 6.44 - 6.42 (2 H, m), 4.86 (2 H, s), 3.41 (2 H, s); 13C NMR 
(150 MHz, DMSO-d6) δ (ppm) 176.02, 141.66, 139.34, 131.85, 128.89, 128.53, 126.68, 
126.59, 126.41, 124.83, 124.41, 46.66, 44.89; IR max/cm-1: 3069, 3038, 2969, 1710; MS 
(ESI) found m/z: 352.4 [M + H]+, C24H17NO2 calculated 351.1. 
 
4-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoic acid  (4s): 
Yield 86%; mp 354-355 oC ; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.90 (2 H, d, J = 8.4 Hz), 
7.53 - 7.50 (2 H, m), 7.33 - 7.30 (2 H, m), 7.22 - 7.19 (4 H, m), 6.63 (2 H, d, J = 8.4 Hz), 4.88 
(2 H, s), 3.44 (2 H, m); 13C NMR (150 MHz, DMSO-d6) δ (ppm) 175.69, 166.49, 141.57, 
139.23, 130.71, 129.86, 126.73, 126.47, 126.41, 124.79, 124.40, 46.74, 44.87; IR max/cm-1: 
3283 (OH stretch), 3020 (CH stretch), 2972 (CH stretch), 1698 (C=O stretch), 1105 (C-O 
stretch); MS (ESI, negative) found m/z: 394.2 [M –H]-, C25H17NO4 calculated 395.1.  
 
Ethyl 4-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl)benzoate (4t): 
Yield 92%; mp 220-222 oC; 1H NMR (600 MHz, acetone-d6) δ (ppm) 7.91 (2 H, d, J = 9.0 
Hz), 7.51 - 7.49 (2 H, m), 7.32 - 7.30 (2 H, m), 7.21 - 7.18 (4 H, m), 67.0 (2 H, d, J = 9.0 Hz), 
4.87 (2 H, s), 4.30 (2 H, q, J = 7.2 Hz), 3.45 (2 H, s), 1.32 (3 H, t,  J= 7.2 Hz); 13C NMR (150 
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MHz, acetone-d6) δ (ppm) 175.42, 165.09, 141.95, 139.62, 129.65, 126.85, 126.67, 126.61, 
124.99, 124.37, 60.86, 47.20, 45.82, 13.67; IR max/cm-1: 2954 (CH stretch), 1707 (C=O 
stretch); MS (ESI) found m/z: 424.5 [M + H]+, C27H21NO4 calculated 423.2.  
 
13-(4-fluorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4u): 
Yield 96%; mp 250-253 oC; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 7.51-7.49 (2 H, m), 7.30 - 
7.29 (2H, m), 7.21 - 7.17 (6 H, m), 6.47 - 6.45 (2 H, m), 4.85 (2 H, m), 3.40 (2 H, m), 13C 
NMR (150 MHz, DMSO-d6) δ  175.85, 161.43 (d, 1JC-F = 244 Hz), 141.53, 139.26, 128.60, 
127.96, 126.59, 126.33, 124.74, 124.33, 115.84 (d, 2JC-F = 23 Hz), 46.59, 44.81; IR max/cm-1: 
2975, 2891, 1708; MS (ESI) found m/z: 370.1 [M + H]+, C24H16FNO2 calculated 369.1. 
 
13-(4-chlorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4v): 
Yield 94%; mp 275-278 oC; 1H NMR (400 MHz, CD2Cl2) δ (ppm) 7.52 - 7.50 (2 H, m), 7.43 (2 
H, d, J = 9.0 Hz) 7.32 - 7.30 (2 H, m), 7.21 – 7.19, (4 H, m) 6.48 (2 H, d, J = 9.0 Hz), 4.87 (2 
H, s), 3.41 (2 H, m); 13C NMR (150 MHz, CD2Cl2) δ (ppm) 175.72, 141.38, 139.01, 134.41, 
130.25, 129.17, 127.86, 127.14, 126.81, 125.05, 124.37, 47.11, 45.88; IR max/cm-1: 2981, 
2973, 2885, 1702; MS (ESI) found m/z: 386.4 [35Cl M + H]+, C24H16ClNO2 calculated 385.1. 
 
13-(4-nitrophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4w):  
Yield 83%; mp 294-295 oC; 1H NMR (600 MHz, DMSO-d6) δ (ppm) 8.22 (2 H, d, J = 9.0 Hz), 
7.51 - 7.50 (2 H, m), 7.31 - 7.30 (2 H, m), 7.20 - 7.18 (4 H, m), 6.81 (2 H, d, J = 9.0 Hz), 4.88 
(1 H, s), 3.45 (2 H, s); 13C NMR (150 MHz, DMSO-d6) δ (ppm) 175.50, 146.79, 141.49, 
139.20, 137.21, 127.34, 126.81, 126.48, 124.80, 124.47, 124.34, 46.84, 44.89; IR max/cm-1: 
3121, 3082, 3017, 2973, 2860, 1708, 1522, 1344; MS (ESI) found m/z: 397.2 [M + H]+, 
C24H16N2O4 calculated 396.1.  
 
13-(4-iodophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione  (4x): 
Yield 89%; mp 303-307 oC; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 7.72 (2 H, d, J = 8.4 Hz), 
7.52 - 7.50 (2 H, m), 7.31 - 7.29 (2 H, m), 7.20 - 7.18 (4 H, m), 6.27 (2 H, d, J = 8.4 Hz), 4.86 
(2 H, s), 3.40 (2 H, s); 13C NMR (100 MHz, DMSO-d6) δ (ppm) 176.23, 142.13, 139.81, 
138.35, 132.02, 129.04, 127.22, 126.96, 125.32, 124.94, 95.17, 47.24, 45.41; IR max/cm-1: 
2973 (CH stretch), 1700 (C=O stretch); MS (ESI) found m/z: 478.4 ([M + H]+), C24H16INO2 
calculated 477.0.  
 
13-(4-(tert-butyl)phenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione (4y): 
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Yield 93%; mp 268-271 oC; 1H NMR (400 MHz, CD2Cl2) δ (ppm) 7.44 – 7.42 (2 H, m), 7.33 - 
7.29 (4 H, m), 7.23 - 7.19 (4 H, m), 6.37 (2 H, d, J = 8.8 Hz), 4.84 - 4.86 (2 H, m), 3.36 (2 H, 
m), 1.26 (9 H, s); 13C NMR (150 MHz, CD2Cl2) δ (ppm) 176.15, 151.98, 141.55, 139.10, 
129.07, 127.07, 126.74, 126.08, 126.03, 125.06, 124.33, 47.11, 45.89, 34.60, 30.95; IR 
max/cm-1: 2963, 2903, 2868, 1707; MS (ESI) found m/z: 408.5 [M + H]+, C28H25NO2 
calculated 407.2. 
 
Biological assays 
Recombinant proteins 
To generate human S100P recombinant protein, a pQE-30 (27.1µg/µl) plasmid encoding 
S100P with N-terminal histidine tags (gifted by Dr Igor Barsukov, Liverpool University, UK), 
was transformed into BL21* competent Escherichia coli cells. Recombinant protein was 
purified using a HisTrap Nickel-nitrilotriacetic acid (Ni-NTA) agarose column (GE Healthcare, 
UK). 
 
ELISA-based binding assay 
Purified recombinant S100P (2µM/well) in phosphate buffer (PBS; 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4; supplemented with 1mM CaCl2, 10 µM 
ZnCl2, and 0.5 mM MgCl2) was used for coating a 96 well plate (NunclonDelta, Fisher), and 
incubated overnight at 37°C. 
Following washing, S100P non-specific binding sites were blocked with 1% bovine serum 
albumin (BSA; Fisher, UK) in PBS for 2 h at 37 °C. Following three washes, S100P was 
incubated with increasing concentrations of compounds, in parallel to cromolyn and DMSO 
treated wells, all in triplicate. Then 30 nM recombinant human receptor for advanced 
glycation end products (rh/RAGE-Fc; R&D Systems) was added and incubated for 1hr at 
37°C. Controls included a negative control (S100P protein, no RAGE-Fc), a positive control 
(S100P protein plus RAGE), and vehicle control (0.001% DMSO in PBS) were included in 
each plate. After three washes in PBS, all wells were exposed to goat anti-human HRP 
conjugate (1:1000; Millipore) for 1 h at 37 °C in order to detect bound receptors. Subsequent 
to washes, wells were incubated for 20 min in the dark with 3,3’,5,5’-tetramethylbenzidene 
(TMB) substrate (Sigma, UK). Plates were read at 450 nm using a Multiskan Ascent 
spectrophotometer (Fisher Scientific, UK). All sample readings were normalized to the 
positive control (S100P plus RAGE-Fc). Statistical analysis was performed and graphs 
plotted using the GraphPad Prism software in the following way: One Way ANOVA was used 
to compare the effects of concentration of each compound to the effects of vehicle control 
(DMSO), and p values of <0.05 were considered statistically significant. A post hoc analysis 
was conducted using Dunnetts multiple comparisons test; results are indicated by * = p 
<0.05; ** = p < 0.01 and *** = p < 0.001. 
 
 
 
Cell culture: MTS cell viability and LDH cytotoxicity assay 
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Human pancreatic cancer cell lines PanC-1 (ATCC- CRL-1469), and BxPC-3 (ATCC-CRL-
1687) were cultured in a humidified atmosphere 5% CO2 (MCO-18AIC (uv) Japan) in 
Dulbecco’s modified eagle’s medium (DMEM)-high glucose (D6429, Sigma, USA) and 
Roswell park memorial institute (RPMI)-1640 medium, respectively, supplemented with 10% 
fetal bovine serum (FBS) (R8758, Sigma, USA), 1% penicillin and streptomycin (Sigma, 
Israel) and 2 mM L-Glutamine (L- glut) (Gibco, UK).  
1x105 Panc-1 cells and 1x105 BxPC-3 cells were plated and allowed to adhere for 24 hrs; the 
cells were treated with cromolyn or the hit compounds for up to 3 days. MTS (CellTiter® 96 
AQueous One Solution assay, Promega) and LDH release (CytoTox-ONE™ Homogeneous 
Membrane Integrity assay, Promega) assays were carried out every 24h for a total of 3 days. 
MTS data was calculated in the following manner: OD for background absorbance was 
subtracted and all samples normalized to untreated cells in order to ascertain whether any 
compound-dependent effect occurred. 
Since formazan formation is proportional to LDH release, data was calculated by subtracting 
the OD background and plotting the mean ± SEM.  
 
Matrigel invasion assay 
The Transwell invasion assay (Fisher Scientific, Germany) was performed using chambers 
with polyethylene terephthalate (PET) membrane filters with 8 µm pore size coated on the 
upper side with Matrigel (a layer of extracellular matrix (ECM) to mimic the process of the 
ECM invasion.   
BxPC-3 and Panc-1 cells were cultured as described above for 24 hours, were re-
suspended and diluted in the appropriate serum-free medium to a seeding density of 2 x 105 
cells/mL and added to the upper chambers of the Transwell invasion chambers. DMEM and 
RPMI-1640 media were supplemented with 10% fetal bovine serum (FBS; Sigma, USA) to 
act as a chemoattractant. 
Controls included untreated cells and vehicle controls cells treated with a relevant 
concentration of DMSO that were both exposed to a chemoattractant in the bottom chamber. 
All other cells were exposed to 10 µM hit compounds with chemoattractant in the bottom 
chamber, and incubated for 48 hours at 37 °C in a humidified atmosphere 5% CO2.  
Cells that had passed through the matrigel coated membrane to the lower surface were fixed 
and stained with Diff-Quik stain kit (Fisher, USA) according to the manufacturer’s 
instructions. The stained membranes were viewed with an inverted microscope (CKX41 
Olympus, Japan x100). The number of invaded cells were counted in five different fields of 
view using the ImageJ 1.50i software (windows version of NIH Image, 
http://rsb.info.nih.gov/nih-image/). 
Compounds were added to cells in the above assays as follows: 0.5 µL of a 10 mM stock 
solution in DMSO was added to the cell medium at a final volume of 0.5 mL, final compound 
concentration 10 µM, final DMSO concentration 0.1%. 
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